New york: Burjeel Holdings, in collaboration with Axiom Space, has unveiled promising findings from their diabetes research initiative, ‘Suite Ride’, conducted aboard the International Space Station (ISS) during Axiom Mission 4 (Ax-4). The research indicates that everyday diabetes management tools can be effectively used in space, transforming the prospects for astronauts with diabetes and enhancing remote healthcare solutions.
According to Emirates News Agency, the study demonstrates that continuous glucose monitors (CGMs) and insulin pens, commonly used by millions on Earth, are feasible for comprehensive diabetes monitoring in space. This breakthrough suggests that astronauts with diabetes may soon be able to participate in space missions, utilizing reliable tools for real-time health management.
To celebrate the success of Suite Ride, Burjeel Holdings announced their ambition to send the first astronaut with diabetes into space. The announcement took place at the Burjeel Institute for Global Health in New York, attended by prominent figures such as Omran Sharaf, Assistant Foreign Minister for Advanced Science and Technology; Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings; and Tejpaul Bhatia, CEO of Axiom Space.
The research was conducted during the Ax-4 mission, where a four-member crew spent 18 days in microgravity. The Suite Ride initiative tested remote care capabilities, focusing on diabetes management in space, and marked a significant step toward inclusive space exploration for individuals with traditionally disqualifying medical conditions.
Initial results indicate that CGMs can provide accurate readings comparable to those on Earth, enabling real-time glucose monitoring in microgravity and facilitating communication of readings back to Earth. This development underscores the potential for space missions to include individuals with diabetes without compromising health and safety.
During a panel discussion, Omran Sharaf highlighted the importance of diverse participation in space exploration. He emphasized that such initiatives generate crucial data for scientific advancement and cater to varied genetic and health needs.
Dr. Mohammad Fityan, Chief Medical Officer at Burjeel Medical City and Clinical Lead of the Burjeel-Ax-4 Space Health Research, stated that the study aligns with the UAE’s space ambitions and represents a pioneering effort in space medicine. The findings are expected to revolutionize healthcare delivery both in space and in remote Earth environments.
The Suite Ride initiative achieved several historic milestones, including the first-ever continuous glucose monitoring and use of insulin pens aboard the ISS. These advancements pave the way for broader inclusion in space exploration and enhance real-time medical monitoring capabilities in extreme conditions.